Recordati bags EUSA to strengthen rare disease franchise

EUSA Pharma, which focuses on rare and niche oncology diseases, was founded in 2015. The company has a portfolio of four niche oncology products, among them monoclonal antibodies for neuroblastoma and Idiopathic Multicentric Castleman’s disease but also a medical device for oral mucositis due to chemo and radio therapy.

The transaction would provide Milan-based Recordati with an expanded portfolio of rare disease pharmaceutical products which is expected to contribute in 2023 revenue of over €150m and EBITDA of
approximately €50m.

We believe that the EUSA Pharma acquisition represents an excellent opportunity to further expand and reinforce our portfolio in a new and underserved therapeutic area, rare and niche oncology, with high potential growth products and will provide a platform for potential further future expansion in these areas. This is another important step forward in delivering on our strategy to increase our presence in the rare disease segment and to fulfil our mission to improve the lives of patients, delivering innovative treatments that address serious unmet medical needs said chairman Andrea Recordati.